Table 1 Patient baseline characteristics among all patients randomised in the Phase II study (NCT00753545) (Ledermann et al, 2012, 2014)
Overall population | BRCA m | g BRCA m | BRCA wt | |||||
|---|---|---|---|---|---|---|---|---|
Olaparib ( n =136) | Placebo ( n =129) | Olaparib ( n =74) | Placebo ( n =62) | Olaparib ( n =53) | Placebo ( n =43) | Olaparib ( n =57) | Placebo ( n =61) | |
Age, years, median (range) | 58 (21–89) | 59 (33–84) | 58 (38–89) | 55 (33–84) | 56 (38–89) | 55 (33–84) | 62 (21–80) | 63 (49–79) |
Jewish ancestry,a n (%) | 20 (15) | 17 (13) | 14 (19) | 14 (23) | 10 (19) | 12 (28) | 6 (11) | 3 (5) |
ECOG performance status, n (%) | ||||||||
0 | 110 (81) | 95 (74) | 62 (84) | 45 (73) | 47 (89) | 32 (74) | 45 (79) | 45 (74) |
1 | 23 (17) | 30 (23) | 11 (15) | 15 (24) | 5 (9) | 10 (23) | 10 (18) | 14 (23) |
2 | 1 (1) | 2 (2) | 0 | 1 (2) | 0 (0) | 1 (2) | 1 (2) | 1 (2) |
Unknown | 2 (2) | 2 (2) | 1 (1) | 1 (2) | 1 (2) | 0 (0) | 1 (2) | 1 (2) |
Primary tumour location, n (%) | ||||||||
Ovary | 119 (88) | 109 (85) | 65 (88) | 54 (87) | 47 (89) | 37 (86) | 50 (88) | 49 (80) |
Fallopian tube or primary peritoneal | 17 (13) | 19 (15) | 9 (12) | 8 (13) | 6 (11) | 6 (14) | 7 (12) | 11 (18) |
Other | 0 | 1 (1) | 0 | 0 | 0 | 0 | 0 | 1 (2) |
Time to progression after completion of most recent platinum-based regimen, n (%) | ||||||||
>6 to ⩽12 months | 53 (39) | 54 (42) | 28 (38) | 26 (42) | 22 (42) | 21 (49) | 23 (40) | 24 (39) |
>12 months | 83 (61) | 75 (58) | 46 (62) | 36 (58) | 31 (58) | 22 (51) | 34 (60) | 37 (61) |
Objective response to most recent platinum-based regimen, n (%) | ||||||||
Complete response | 57 (42) | 63 (49) | 36 (49) | 34 (55) | 29 (55) | 22 (51) | 20 (35) | 25 (41) |
Partial response | 79 (58) | 66 (51) | 38 (51) | 28 (45) | 24 (45) | 21 (49) | 37 (65) | 36 (59) |
